VRDN Viridian Therapeutics, Inc.\DE

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core biopharma focus on autoimmune and rare diseases, emphasizing best-in-class therapies for thyroid eye disease (TED) and related conditions
• • New subcutaneous IGF-1R antibody elegrobart in pivotal phase 3 (REVEAL-1/2) for TED with potential auto-injector, complementing intravenous veligrotug

Risk Factors

• • Regulatory risk: FDA may require additional patients or steps for veligrotug and elegrobart phase 3 trials, risking approval delays or denials
• • Geopolitical exposure: Clinical trial operations in Israel and China vulnerable to adverse regulatory actions or unrest impacting progress

Management Discussion & Analysis

• • Revenue $70.8M in 2025 vs $0.3M in 2024; increase driven by $70M upfront license payment from Kissei and related party collaborations
• • Research & Development expenses $338.9M in 2025 vs $238.3M in 2024; TED portfolio R&D up $78.3M, driven by phase 3 trials and milestone fees

Risk Factors

• • New risk: Potential failure to meet DRI Purchase and Sale Agreement milestones after October 2025, risking up to $245M in milestone payments
• • Updated clinical development risk: FDA may require additional patients beyond 300 in safety databases for veligrotug and VRDN-003, potentially delaying approvals

What are the latest VRDN SEC filings in 2026?

Viridian Therapeutics, Inc.\DE (VRDN) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did VRDN file its most recent 10-K annual report?

Viridian Therapeutics, Inc.\DE (VRDN) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view VRDN 10-Q quarterly reports?

Viridian Therapeutics, Inc.\DE (VRDN)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every VRDN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has VRDN filed recently?

Viridian Therapeutics, Inc.\DE (VRDN)'s most recent 8-K was filed on March 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find VRDN insider trading activity (Form 4)?

SignalX aggregates every VRDN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does VRDN file with the SEC?

Viridian Therapeutics, Inc.\DE (VRDN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VRDN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Viridian Therapeutics, Inc.\DE (VRDN).

What is VRDN's SEC CIK number?

Viridian Therapeutics, Inc.\DE (VRDN)'s SEC CIK (Central Index Key) number is 1590750. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1590750 to look up all VRDN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find VRDN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Viridian Therapeutics, Inc.\DE (VRDN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.